Computational Study on Protein-Ligand Interactions for Anti-Diabetic

CHF 90.60
Auf Lager
SKU
QCQJS7M8P8M
Stock 1 Verfügbar
Free Shipping Kostenloser Versand
Geliefert zwischen Di., 07.10.2025 und Mi., 08.10.2025

Details

India is a world capital of diabetes, hence it is required immediate attention of drug design and development of novel drug. Though Type 2 Diabetes has many drugs, it lacks 100% effective cure. Drug design is mainly based on protein-ligand interactions and the active site residues. Advances in computational techniques have enabled virtual screening to have a positive impact on the discovery process. In ligand-based virtual screening, the strategy is to use information provided by a compound or set of compounds that are known to bind to the desired target and to use this to identify other compounds in the corporate database or external databases with similar properties. Most effective ligand binding to the protein can be known by this database which makes the drug design effective and easy.

Autorentext

Dr.Naresh working as Associate Professor in the Department of CSE, Avanthi's Research & Technological Academy. He attain his Bachelors Degree from Andhra University in 2003, Masters degree from Andhra University in 2006, Doctorate from Acharya Nagarajuna University in 2012. He published 10 papers in various journals. Since 8 years he is in teaching

Cart 30 Tage Rückgaberecht
Cart Garantie

Weitere Informationen

  • Allgemeine Informationen
    • Sprache Englisch
    • Untertitel In silico Study
    • Autor Naresh Babu Muppalaneni
    • Titel Computational Study on Protein-Ligand Interactions for Anti-Diabetic
    • ISBN 978-3-659-10481-7
    • Format Kartonierter Einband (Kt)
    • EAN 9783659104817
    • Jahr 2012
    • Größe H220mm x B220mm
    • Herausgeber LAP Lambert Academic Publishing
    • Anzahl Seiten 172
    • Auflage Aufl.
    • Genre Ratgeber & Freizeit
    • GTIN 09783659104817

Bewertungen

Schreiben Sie eine Bewertung
Nur registrierte Benutzer können Bewertungen schreiben. Bitte loggen Sie sich ein oder erstellen Sie ein Konto.